Supplement
NAD+ precursor with growing human data.[2906,4022,4121, etc.]
Superscript reference numbers link to the Sources bibliography.
Composite Rating
Blends evidence depth, community direction, safety friction, and completeness.
Evidence Intensity
100/100
High depth from human/RCT/meta counts
Community Direction
-6
Mixed / Neutral • confidence Minimal
Safety Friction
100/100
High signal from adverse/interaction markers
Data Completeness
100%
Studies 14 • mentions 5 • links 24
Not medical advice. This product is for educational and informational purposes only. It does not diagnose, treat, cure, or prevent any disease and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.
FDA disclaimer: These statements have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Results may vary. Not intended for use by pregnant or nursing women, individuals under 18, or those with known medical conditions without physician consultation.
If you are experiencing a medical emergency, call 911 or your local emergency number immediately.
Goal alignment: Longevity, Energy, Metabolic Health.[583,731,955, etc.]
Dose guide: Human-study daily dose: 300 mg-900 mg/day (higher-confidence extraction from PubMed abstracts)..[583,731,955, etc.]
Category
Cofactor
Evidence Tier
HIGH
Daily Guide
Human-study daily dose: 300 mg-900 mg/day (higher-confidence extraction from PubMed abstracts).
Dosing Guide
Human-study daily dose: 300 mg-900 mg/day (higher-confidence extraction from PubMed abstracts).[2906,, etc.]
Clinical Depth
Humans: 137 • RCTs: 11 • Meta: 4
Cohort / Real-World
Cohort signals: 0
Safety Markers
Adverse signals: 59 • Interactions: 104
Freshness, trend, and study timeline for this item
Status
Trend
↑ Growing evidence base
Depth
332 total studies · 5 recent
Timeline
Animal-only studies
493
Total indexed
332
In vitro / tissue
254
Human studies
137
Interaction signals
104
Safety adverse signals
59
Weighted direction score: -6 (Mixed / Neutral)
High when >=2 human meta-analyses, or >=5 human RCTs with substantial human literature volume.
Animal-only studies
493
Total indexed
332
In vitro / tissue
254
Human studies
137
Interaction signals
104
Safety adverse signals
59
Randomized trials
11
Meta-analyses
4
Distribution of evidence by study design strength
Evidence Strength: High
Composite of study volume, RCTs, and meta-analyses
PMID 39531138 • 2024 Nov 12
Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials.
Curr Diab Rep
Open PubMedPMID 39185644 • 2025
Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-aged and Elderly: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Curr Pharm Biotechnol
Open PubMedPMID 40275690 • 2025 Jun
Benefit reports: 2
Adverse reports: 2
No-effect reports: 0
Mixed reports: 1
Unclear reports: 0
Signal confidence: 0.00
Benefits
Adverse
No Effect
Pricing and purity verification are major concerns. | Step2: Insufficient empirical signal for a directional adjustment.
aggregate • unclear
Aggregate community signal: 5 directional mentions (benefit 2, adverse 2, no-effect 0, mixed 1).
Open mentionamazon
Amazon search for Nicotinamide Mononucleotide (NMN)
Rating: n/a | Reviews: n/a
Open productEvidence Sources
RCT • 2023 • Adults
Middle-aged adults in small trials.
Outcome: Possible metabolic improvements with variable magnitude.[2906,4022,4121, etc.]
PUBMED • Humans + preclinical triage
Counts aggregated from automated literature sweep and tiering rules.
Outcome: Tier HIGH; humans 137, RCTs 11, meta-analyses 4.[2906,4022,4121, etc.]
Open sourceThe Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
J Cachexia Sarcopenia Muscle
PMID 39116016 • 2025
Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials.
Crit Rev Food Sci Nutr
Open PubMedPMID 36482258 • 2023 Feb
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.
Geroscience
Open PubMedPMID 33888596 • 2021 Jun 11
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.
Science
Open PubMedPMID 34238308 • 2021 Jul 8
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.
J Int Soc Sports Nutr
Open PubMedPMID 36797393 • 2023 Feb 16
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial.
Sci Rep
Open PubMedPMID 35215405 • 2022 Feb 11
Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study.
Nutrients
Open PubMedPMID 38789831 • 2024 Oct
Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study.
Geroscience
Open PubMedPMID 37619764 • 2023 Nov
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update.
Adv Nutr
Open PubMedPMID 35499054 • 2022 Mar
Nicotinamide mononucleotide (NMN) as an anti-aging health product - Promises and safety concerns.
J Adv Res
Open PubMedPMID 37068054 • 2023 Dec 1
Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.
J Gerontol A Biol Sci Med Sci
Open PubMedPMID 29249689 • 2018 Mar 6
NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR.
Cell Metab
Open PubMedReddit evidence: 0 mentions (confidence 0.00).
Amazon signal: 0 products scanned (confidence 0.00).
GNC signal: 0 products scanned (confidence 0.00) [BLOCKED].
PerimeterX / captcha block encountered.
Search fetch failed: Failed to fetch after retries: https://old.reddit.com/search.json?raw_json=1&sort=relevance&t=year&limit=12&q=%22nicotinamide%20mononucleotide%22%20(supplement%20OR%20dosage%20OR%20stack%20OR%20side%20effects%20OR%20review)%20(subreddit%3ASupplements%20OR%20subreddit%3ANootropics%20OR%20subreddit%3ABiohackers%20OR%20subreddit%3Alongevity%20OR%20subreddit%3ANutrition%20OR%20subreddit%3AHubermanLab%20OR%20subreddit%3ASleep%20OR%20subreddit%3AFitness%20OR%20subreddit%3Aketoscience%20OR%20subreddit%3AStackAdvice)
Fallback search failed: Failed to fetch after retries: https://old.reddit.com/search.json?raw_json=1&sort=comments&t=all&limit=16&q=%22nicotinamide%20mononucleotide%22%20(supplement%20OR%20capsule%20OR%20powder%20OR%20experience%20OR%20results%20OR%20side%20effects)
Broad search failed: Failed to fetch after retries: https://old.reddit.com/search.json?raw_json=1&sort=new&t=all&limit=16&q=nicotinamide%20mononucleotide
Use adverse/interactions PubMed signal counts for screening; perform clinician review before high-dose or multi-drug stack use.
Human-study daily dose signal: 300 mg-900 mg/day (confidence HIGH).
Extracted from 6 dosing mentions across 2 PubMed studies (mg/day).
Imported legacy community score: 9.0/10 (heuristic mapping confidence 1.00).
Imported legacy monthly cost signal: ~$50.00.
Legacy community note: The flagship longevity supplement. Community reports improved energy, better sleep, mental clarity, and exercise capacity. David Sinclair's personal use has driven enormous interest. Some debate NMN vs NR. Sublingual delivery gaining popularity.
Community Sources
PUBMED • 2024 • Human evidence curation set
PMID 39531138 from Curr Diab Rep.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2025 • Human evidence curation set
PMID 39185644 from Curr Pharm Biotechnol.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2025 • Human evidence curation set
PMID 40275690 from J Cachexia Sarcopenia Muscle.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2025 • Human evidence curation set
PMID 39116016 from Crit Rev Food Sci Nutr.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2023 • Human evidence curation set
PMID 36482258 from Geroscience.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2021 • Human evidence curation set
PMID 33888596 from Science.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2021 • Human evidence curation set
PMID 34238308 from J Int Soc Sports Nutr.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2023 • Human evidence curation set
PMID 36797393 from Sci Rep.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2022 • Human evidence curation set
PMID 35215405 from Nutrients.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2024 • Human evidence curation set
PMID 38789831 from Geroscience.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2023 • Human evidence curation set
PMID 37619764 from Adv Nutr.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2022 • Human evidence curation set
PMID 35499054 from J Adv Res.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2023 • Human evidence curation set
PMID 37068054 from J Gerontol A Biol Sci Med Sci.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open sourcePUBMED • 2018 • Human evidence curation set
PMID 29249689 from Cell Metab.
Outcome: See linked PubMed abstract for methods and outcomes.[2906,4022,4121, etc.]
Open source